On the whole, given the role of TCPTP in glucose metabolism by regulating insulin, leptin and other signaling pathways, this review considers that the development of specific and effective TCPTP inhibitors for individual cells, tissues or organs is a promising therapeutic strategy for diabetes or obesity. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.